Altimmune (ALT) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Agriculture Air Conservation Environment Environmental Environmental Protection Escape Materials Nature Nuclear Offset Package Packaging Pandemic Raw Materials Regenerative Toxic Waste Access African American Asian Benefits Black California Consumer Privacy Act Charitable Collective Bargaining Community Culture Customer Cybersecurity Data Privacy Data Security Death Demographic Demographics Disability Diversity Drug Pricing Employee Engagement Ethnic Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Injury Latinx LGBTQ Minority Perquisites Privacy Product Quality Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Workforce Assessment Assurance Attorneys General Audit Bonus Bribery Chronic Class Action Lawsuit Classified Commitment Corporate Governance Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Plaintiff Pledging Procurement Purpose Quality Standard R&D Refresh the Board Reputation Reputational Research and Development Responsibility Responsible Stockholder Engagement Strategy Sustainable Targets Tax Tenure Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On September 29, 2022, Altimmune, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”). As of August 12, 2022, the record date for the 2022 Annual Meeting, there were 49,024,358 shares of the Company’s common stock outstanding and entitled to vote at the 2022 Annual Meeting. A total of 36,609,662 shares of common stock were present or represented by proxy at the 2022 Annual Meeting, representing 74.68% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows:
Proposal No. 1: Election of Directors. The results were as follows:

Director	For	Withhold	Non-Votes

			Broker
Mitchel Sayare, Ph.D.	23,901,926	101,662	12,606,074
Vipin K. Garg, Ph.D.	23,896,828	106,760	12,606,074
David J. Drutz, M.D.	19,939,625	4,063,963	12,606,074
John M. Gill	19,940,007	4,063,581	12,606,074
Philip L. Hodges	23,903,614	99,974	12,606,074
Diane Jorkasky, M.D.	23,903,684	99,904	12,606,074
Wayne Pisano	19,705,074	4,298,514	12,606,074
Klaus O. Schafer, M.D., MPH	23,902,014	101,574	12,606,074

Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022. The results were as follows:


For	Against	Abstain
36,417,212	103,172	89,278

Proposal No. 3: Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal). The results were as follows:

For		Against		Abstain		Broker Non-Votes

17,483,146		6,452,469		67,973		12,606,074

Proposal No. 4: Vote to authorize the adjournment of the 2022 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows:


For	Against	Abstain
26,130,153	10,300,107	179,402